{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:20Z","timestamp":1790878340283,"version":"4.1.0"},"reference-count":48,"publisher":"Informa UK Limited","issue":"14","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.2217\/fon-2021-1634","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T09:33:37Z","timestamp":1645090417000},"page":"1669-1678","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-1171","authenticated-orcid":false,"given":"Jean","family":"Bourhis","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire Vaudois,\rLausanne,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Burtness","sequence":"additional","affiliation":[{"name":"Yale School of Medicine & Yale Cancer Center,\rNew Haven,\rCT 06510,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa F","family":"Licitra","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori & University of Milan,\rMilan,\rItaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nutting","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust,\rLondon,\rUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D","family":"Schoenfeld","sequence":"additional","affiliation":[{"name":"Brigham & Women\u2019s Hospital & Dana-Farber Cancer Institute,\rBoston,\rMA 02215,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokhtar","family":"Omar","sequence":"additional","affiliation":[{"name":"Debiopharm International SA,\rLausanne,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florilene","family":"Bouisset","sequence":"additional","affiliation":[{"name":"Debiopharm International SA,\rLausanne,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Nauwelaerts","sequence":"additional","affiliation":[{"name":"Debiopharm International SA,\rLausanne,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Urfer","sequence":"additional","affiliation":[{"name":"Debiopharm International SA,\rLausanne,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zanna","sequence":"additional","affiliation":[{"name":"Debiopharm International SA,\rLausanne,\rSwitzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra EW","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of California,\rSan Diego,\rLa Jolla,\rCA 92093,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds299"},{"key":"e_1_3_6_4_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology . Head and neck cancer. v1.2021. www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00199"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2017.05.008"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6995"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0662-5"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1715715"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3747\/co.24.3489"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0157"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.14639\/0392-100X-suppl.1-40-2020"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00072"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102371"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"e_1_3_6_18_1","volume-title":"Opdivo (nivolumab) [prescribing information].","year":"2019","unstructured":"Opdivo (nivolumab) [prescribing information]. Bristol Myers Squibb, NJ, USA (2019)."},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"key":"e_1_3_6_21_1","unstructured":"Keytruda (pembrolizumab) [prescribing information]. Merck & Co. Inc NJ USA (2019)."},{"key":"e_1_3_6_22_1","unstructured":"Keytruda (pembrolizumab) [summary of product characteristics]. Merck & Co Haarlem The Netherlands (2020)."},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.036"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.04.014"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041800"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030663"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00197"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9041012"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800908783769373"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/35050006"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30327-2"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3627"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010207"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14129"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.20563"},{"issue":"19","key":"e_1_3_6_37_1","article-title":"Effects of Debio1143, a novel oral IAP inhibitor, in monotherapy and combination with platinum drugs in human SCCHN tumor specimens","volume":"74","author":"Serova M","year":"2014","unstructured":"Serova M , Tijras-RaballandA, AlbertSet al. Effects of Debio1143, a novel oral IAP inhibitor, in monotherapy and combination with platinum drugs in human SCCHN tumor specimens. Cancer Res.74(Suppl. 19), Abstract 2752 (2014).","journal-title":"Cancer Res."},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm101505d"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35860-z"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.05.017"},{"issue":"13","key":"e_1_3_6_41_1","article-title":"Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck","volume":"79","author":"Gomez-Roca C","year":"2019","unstructured":"Gomez-Roca C , EvenC, TourneauCLet al. Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients with resectable squamous cell carcinoma of the head and neck. Cancer Res.79(Supplement 13), Abstract 5001 (2019).","journal-title":"Cancer Res."},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.15171\/apb.2017.041"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-1250-3"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24064"},{"issue":"8","key":"e_1_3_6_45_1","article-title":"The SMAC-mimetic Debio 1143 efficiently enhanced chemo and radiotherapy in head and neck squamous cell carcinoma models","volume":"73","author":"Viertl D","year":"2013","unstructured":"Viertl D , Perillo-AdamerF, RigottiSet al. The SMAC-mimetic Debio 1143 efficiently enhanced chemo and radiotherapy in head and neck squamous cell carcinoma models. Cancer Res.73(Supplement 8), Abstract 2055 (2013).","journal-title":"Cancer Res."},{"key":"e_1_3_6_46_1","first-page":"928120","article-title":"The opposing roles of cellular inhibitor of apoptosis proteins in cancer","volume":"2012","author":"Lau R","year":"2012","unstructured":"Lau R , PrattMA. The opposing roles of cellular inhibitor of apoptosis proteins in cancer. ISRN Oncol.2012, 928120 (2012).","journal-title":"ISRN Oncol."},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101123"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00312-6"},{"issue":"1168","key":"e_1_3_6_49_1","article-title":"3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck","volume":"31","author":"Bourhis J","year":"2020","unstructured":"Bourhis J , SunX, LeTourneau Cet al. 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck. Ann. Oncol.31(S1168); Abstract LBA 1139 (2020).","journal-title":"Ann. Oncol."},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:00Z","timestamp":1719125160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.2217\/fon-2021-1634"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1634","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}